Drug Discovery@nature.com 12 September 2014

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS 19 September 2014 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement A new open access, multi-and interdisciplinary journal dedicated to publishing the highest quality papers on aging and age-related diseases, the journal is now open for submissions.  Explore the benefits of submitting your next research article.   News Top Japan stem-cell trial stirs envy doi:10.1038/513287a Researchers elsewhere can't wait to test iPS cells in humans. Full Text Market watch: Upcoming catalysts in Q4 2014 doi:10.1038/nrd4449 After the recent successful launch of the breakthrough hepatitis C virus (HCV) drug sofosbuvir, additional competitors are imminent, with the US FDA expected to deliver decisions on several marketing applications for all-oral HCV drug regimens in the fourth quarter of the year. Full Text Vaginal microbe yields novel antibiotic doi:10.1038/nature.2014.15900 Drug is one of thousands that may be produced by the human microbiome. Full Text FDA pushes for control over laboratory-developed tests doi:10.1038/nbt0914-855a The US Food and Drug Administration has told Congress that it intends to enforce its oversight over laboratory-developed tests. Full Text Analysis Top The HIV pipeline doi:10.1038/nrd4364 This article provides an overview of the diverse anti-HIV agents in development, including combination therapies, and an analysis of the market for current and future HIV treatments. Full Text Kinase convergence on eIF4F doi:10.1038/scibx.2014.1030 Researchers have shown that the eIF4F complex is a hub in which resistance pathways for BRAF and MEK converge and suggest that combining eIF4F inhibitors with marketed melanoma drugs could circumvent resistance. Full Text Research Highlights Top Epilepsy: Endocannabinoid metabolism offers handle to dampen down excitability doi:10.1038/nrd4418 Targeting the serine hydrolase α/β-hydrolase domain 6, which is involved in endocannabinoid metabolism, can protect against seizures in mouse models of epilepsy. Full Text Obesity and diabetes: FGF1 goes long to tackle diabetes doi:10.1038/nrd4419 Subcutaneous delivery of fibroblast growth factor 1 (FGF1) confers novel insulin-sensitizing properties to this molecule in diabetic mice while avoiding many of the side effects associated with current antidiabetic drugs. Full Text Neurodevelopmental disorders: Righting Rett syndrome with IGF1 doi:10.1038/nrd4417 Two papers show that treatment with insulin-like growth factor 1 (IGF1) and/or the β2-adrenergic receptor agonist clenbuterol can alleviate symptoms in mouse models of Rett syndrome. Full Text Research & Reviews Top Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies doi:10.1038/nrd4363 Biological drugs offer high specificity and potency, but their formulation and delivery pose substantial challenges. This article highlights recent advances in formulation strategies, describes current and emerging delivery routes and reviews the potential of targeted and intracellular delivery of biologics. Full Text Strategies to improve drug development for sepsis doi:10.1038/nrd4368 Despite numerous clinical trials, no specific therapeutic agent is currently approved for sepsis. Here, Fink and Warren consider potential reasons for such failures and suggest possible strategies to overcome ongoing challenges, such as improving clinical trial design. Full Text Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders doi:10.1038/nrd4360 Histone deacetylases (HDACs) are a class of epigenetic enzymes that remove acetyl groups from lysine residues on histones and other proteins. In this review, the authors highlight the role of HDACs in cancer, neurological diseases and immune disorders, and discuss the development of small-molecule inhibitors. Full Text Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders doi:10.1038/nrd4308 Compared to traditional drugs that target the orthosteric ligand-binding site of GPCRs, allosteric modulators have the potential to achieve greater subtype selectivity and allow the normal function of endogenous ligands to be preserved. Conn and colleagues reflect on the key principles for successful optimization of GPCR allosteric modulators. Full Text Drug Discovery JOBS of the week Faculty Position in Medicinal Chemistry for Cancer Drug Discovery St. Jude Children's Research Hospital (SJCRH) Non-invasive diagnosis and drug screening in neurological infections KU Leuven PhD scholarship in Drug Delivery Technical University of Denmark (DTU) Head of Drug and RNAi Screening Platform UCLA Professorship (W2) "Phospholipids in Drug Development" Friedrich Schiller University Jena More Science jobs from Drug Discovery EVENT 6th Annual Global Drug Delivery & Formulation Summit 09.02.15 Dusseldorf, Germany More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.